Staff – University of Copenhagen

Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: Study protocol for a randomized controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn : Study protocol for a randomized controlled trial. / Halkjær, Sofie Ingdam; Nilas, Lisbeth; Carlsen, Emma Malchau; Cortes, Dina; Halldórsson, Thórhallur Ingi; Olsen, Sjurdur Frodi; Pedersen, Anders Elm; Krogfelt, Karen Angeliki; Petersen, Andreas Munk.

In: Trials, Vol. 17, 491, 11.10.2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Halkjær, SI, Nilas, L, Carlsen, EM, Cortes, D, Halldórsson, TI, Olsen, SF, Pedersen, AE, Krogfelt, KA & Petersen, AM 2016, 'Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: Study protocol for a randomized controlled trial' Trials, vol. 17, 491. https://doi.org/10.1186/s13063-016-1617-5

APA

Halkjær, S. I., Nilas, L., Carlsen, E. M., Cortes, D., Halldórsson, T. I., Olsen, S. F., ... Petersen, A. M. (2016). Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: Study protocol for a randomized controlled trial. Trials, 17, [491]. https://doi.org/10.1186/s13063-016-1617-5

Vancouver

Halkjær SI, Nilas L, Carlsen EM, Cortes D, Halldórsson TI, Olsen SF et al. Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: Study protocol for a randomized controlled trial. Trials. 2016 Oct 11;17. 491. https://doi.org/10.1186/s13063-016-1617-5

Author

Halkjær, Sofie Ingdam ; Nilas, Lisbeth ; Carlsen, Emma Malchau ; Cortes, Dina ; Halldórsson, Thórhallur Ingi ; Olsen, Sjurdur Frodi ; Pedersen, Anders Elm ; Krogfelt, Karen Angeliki ; Petersen, Andreas Munk. / Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn : Study protocol for a randomized controlled trial. In: Trials. 2016 ; Vol. 17.

Bibtex

@article{c16038b3ec17493e803916d2e6692335,
title = "Effects of probiotics (Vivomixx{\circledR}) in obese pregnant women and their newborn: Study protocol for a randomized controlled trial",
abstract = "Background: Maternal obesity is associated with increased risks of adverse pregnancy-related complications and outcomes for both mothers and infants. Overweight and obese women have an increased risk of pregnancy-induced hypertension, preeclampsia and gestational diabetes mellitus (GDM). Infant Body Mass index (BMI) and the risk of obesity in adulthood are related to maternal gestational weight gain (GWG). Preventive lifestyle and dietary interventions are time-consuming and do not always reduce GWG or the risk of maternal pregnancy complications. Recent research has indicated that the gut microbiota may play a significant role in the development of obesity. Some studies have indicated that the daily consumption of probiotics may reduce the risk of preeclampsia, maintain serum insulin levels and reduce the frequency of GDM in pregnant women. The aims of this study are to investigate whether daily probiotic supplements in obese women during pregnancy can limit gestational weight gain, improve glucose homeostasis and thereby improve maternal, fetal and infant health outcomes. Methods: A pilot study including 50 obese pregnant nulliparous women with a prepregnancy BMI of between 30 and 35 kg/m2 will be randomized to receive daily probiotics (four capsules of Vivomixx{\circledR}; total of 450 billion CFU/day, including eight probiotic bacterial strains) or placebo from gestational age 14-20 weeks until delivery. The infants will be followed until 9 months of age. The women will be monitored by weight, blood, fecal, vaginal and urine samples, diet questionnaires and hospital record review. Primary outcomes are: maternal weight gain, glycated hemoglobin (HbA1c) level and changes in glucose concentration measured during an oral glucose tolerance test. Secondary outcomes are: microbiota and inflammatory markers in mother and child, pregnancy complications, pregnancy outcomes, physical activity and the body composition of the neonate. Discussion: We expect to find alterations in the metabolic profiles, microbiota and possibly pregnancy outcomes. From a clinical point of view the effects of Vivomixx{\circledR} could control weight gain and reduce complications during pregnancy by inducing changes in the gut microbiota. Furthermore, this intervention during pregnancy could influence the infant's microbiota, which could have important implications for infant development and health. Trial registration: ClincalTrials.gov Identifier: NCT02508844, registered on 11 May 2015.",
keywords = "Gestational diabetes mellitus, Microbiota, Obesity, Pregnancy, Probiotics, Study protocol, Vivomixx{\circledR}",
author = "Halkj{\ae}r, {Sofie Ingdam} and Lisbeth Nilas and Carlsen, {Emma Malchau} and Dina Cortes and Halld{\'o}rsson, {Th{\'o}rhallur Ingi} and Olsen, {Sjurdur Frodi} and Pedersen, {Anders Elm} and Krogfelt, {Karen Angeliki} and Petersen, {Andreas Munk}",
year = "2016",
month = "10",
day = "11",
doi = "10.1186/s13063-016-1617-5",
language = "English",
volume = "17",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn

T2 - Study protocol for a randomized controlled trial

AU - Halkjær, Sofie Ingdam

AU - Nilas, Lisbeth

AU - Carlsen, Emma Malchau

AU - Cortes, Dina

AU - Halldórsson, Thórhallur Ingi

AU - Olsen, Sjurdur Frodi

AU - Pedersen, Anders Elm

AU - Krogfelt, Karen Angeliki

AU - Petersen, Andreas Munk

PY - 2016/10/11

Y1 - 2016/10/11

N2 - Background: Maternal obesity is associated with increased risks of adverse pregnancy-related complications and outcomes for both mothers and infants. Overweight and obese women have an increased risk of pregnancy-induced hypertension, preeclampsia and gestational diabetes mellitus (GDM). Infant Body Mass index (BMI) and the risk of obesity in adulthood are related to maternal gestational weight gain (GWG). Preventive lifestyle and dietary interventions are time-consuming and do not always reduce GWG or the risk of maternal pregnancy complications. Recent research has indicated that the gut microbiota may play a significant role in the development of obesity. Some studies have indicated that the daily consumption of probiotics may reduce the risk of preeclampsia, maintain serum insulin levels and reduce the frequency of GDM in pregnant women. The aims of this study are to investigate whether daily probiotic supplements in obese women during pregnancy can limit gestational weight gain, improve glucose homeostasis and thereby improve maternal, fetal and infant health outcomes. Methods: A pilot study including 50 obese pregnant nulliparous women with a prepregnancy BMI of between 30 and 35 kg/m2 will be randomized to receive daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day, including eight probiotic bacterial strains) or placebo from gestational age 14-20 weeks until delivery. The infants will be followed until 9 months of age. The women will be monitored by weight, blood, fecal, vaginal and urine samples, diet questionnaires and hospital record review. Primary outcomes are: maternal weight gain, glycated hemoglobin (HbA1c) level and changes in glucose concentration measured during an oral glucose tolerance test. Secondary outcomes are: microbiota and inflammatory markers in mother and child, pregnancy complications, pregnancy outcomes, physical activity and the body composition of the neonate. Discussion: We expect to find alterations in the metabolic profiles, microbiota and possibly pregnancy outcomes. From a clinical point of view the effects of Vivomixx® could control weight gain and reduce complications during pregnancy by inducing changes in the gut microbiota. Furthermore, this intervention during pregnancy could influence the infant's microbiota, which could have important implications for infant development and health. Trial registration: ClincalTrials.gov Identifier: NCT02508844, registered on 11 May 2015.

AB - Background: Maternal obesity is associated with increased risks of adverse pregnancy-related complications and outcomes for both mothers and infants. Overweight and obese women have an increased risk of pregnancy-induced hypertension, preeclampsia and gestational diabetes mellitus (GDM). Infant Body Mass index (BMI) and the risk of obesity in adulthood are related to maternal gestational weight gain (GWG). Preventive lifestyle and dietary interventions are time-consuming and do not always reduce GWG or the risk of maternal pregnancy complications. Recent research has indicated that the gut microbiota may play a significant role in the development of obesity. Some studies have indicated that the daily consumption of probiotics may reduce the risk of preeclampsia, maintain serum insulin levels and reduce the frequency of GDM in pregnant women. The aims of this study are to investigate whether daily probiotic supplements in obese women during pregnancy can limit gestational weight gain, improve glucose homeostasis and thereby improve maternal, fetal and infant health outcomes. Methods: A pilot study including 50 obese pregnant nulliparous women with a prepregnancy BMI of between 30 and 35 kg/m2 will be randomized to receive daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day, including eight probiotic bacterial strains) or placebo from gestational age 14-20 weeks until delivery. The infants will be followed until 9 months of age. The women will be monitored by weight, blood, fecal, vaginal and urine samples, diet questionnaires and hospital record review. Primary outcomes are: maternal weight gain, glycated hemoglobin (HbA1c) level and changes in glucose concentration measured during an oral glucose tolerance test. Secondary outcomes are: microbiota and inflammatory markers in mother and child, pregnancy complications, pregnancy outcomes, physical activity and the body composition of the neonate. Discussion: We expect to find alterations in the metabolic profiles, microbiota and possibly pregnancy outcomes. From a clinical point of view the effects of Vivomixx® could control weight gain and reduce complications during pregnancy by inducing changes in the gut microbiota. Furthermore, this intervention during pregnancy could influence the infant's microbiota, which could have important implications for infant development and health. Trial registration: ClincalTrials.gov Identifier: NCT02508844, registered on 11 May 2015.

KW - Gestational diabetes mellitus

KW - Microbiota

KW - Obesity

KW - Pregnancy

KW - Probiotics

KW - Study protocol

KW - Vivomixx®

U2 - 10.1186/s13063-016-1617-5

DO - 10.1186/s13063-016-1617-5

M3 - Journal article

VL - 17

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 491

ER -

ID: 169103563